Product Information
THEO-24 ER 300 MG CAPSULE is a brand (anda) product labeled by Endo USA Inc., priced at $6.9529 per EA under NDC 52244030010. Its NADAC has been published 612 times since Jan 14, 2015.
Strength
300 mg/1
Manufacturer
Endo USA Inc.NDC
52244030010
Classification
Brand (ANDA)
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
THEOPHYLLINE ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA087944On Market Since
8/25/2014
Pharmacological Classes
Price Statistics
The NADAC for THEO-24 ER 300 MG CAPSULE has been published 612 times since Jan 14, 2015, and over the history we have for it it has risen 184.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.9529 per EA |
|---|---|
| All-time high | $6.9596 (Aug 12, 2026) |
| All-time low | $2.4436 (Jan 14, 2015) |
| 52-week high | $6.9596 |
| 52-week low | $6.7427 |
| Median price | $4.2374 |
| Average price | $4.5494 |
| Largest weekly change | +10.0% (Jul 13, 2016) |
| Weeks tracked | 612 |
| Tracking since | Jan 14, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the theophylline anhydrous market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
theophylline anhydrous market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Methylxanthine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THEO-24 ER 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for THEO-24 ER 300 MG CAPSULE, manufactured by Endo USA Inc., is $6.9529 per EA (NDC 52244030010), effective Sep 30, 2026.
How has the price of THEO-24 ER 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for THEO-24 ER 300 MG CAPSULE has risen 184.5%. It has been tracked across 612 weekly CMS publications since Jan 14, 2015.
What are the highest and lowest recorded NADAC prices for THEO-24 ER 300 MG CAPSULE?
Since Jan 14, 2015, the NADAC for THEO-24 ER 300 MG CAPSULE has ranged from a low of $2.4436 (Jan 14, 2015) to a high of $6.9596 (Aug 12, 2026), with a median of $4.2374 per EA.
Are there cheaper alternatives to THEO-24 ER 300 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of THEO-24 ER 300 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures THEO-24 ER 300 MG CAPSULE?
THEO-24 ER 300 MG CAPSULE (NDC 52244030010) is labeled by Endo USA Inc., and CMS classifies it as a brand (anda) product.